Atlas Trials

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Clinical trial NCT05325229 · UNKNOWN

Trial details

NCT number
NCT05325229
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Platinum-resistant Recurrent Ovarian Cancer
Start date
2022-08-18
Primary completion
2024-12-01
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.